메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 30, Issue 33, 2012, Pages 4061-4063
Boulevard of broken dreams: Drug approval for older adults with acute myeloid leukemia
Author keywords

[No Author keywords available]
Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE INHIBITOR; GEMTUZUMAB OZOGAMICIN; LAROMUSTINE; TIPIFARNIB;
EID: 84869458541     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.2962     Document Type: Note
Times cited : (32)
References (15)
  • 1
    • 0015721940 scopus 로고
    • Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia
    • Yates JW, Wallace HJ Jr, Ellison RR, et al: Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57:485-488, 1973
    • (1973) Cancer Chemother Rep , vol.57 , pp. 485-488
    • Yates, J.W.1    Wallace Jr., H.J.2    Ellison, R.R.3
  • 2
    • 70149093912 scopus 로고    scopus 로고
    • Recurring mutations found by sequencing an acute myeloid leukemia genome
    • Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
    • (2009) N Engl J Med , vol.361 , pp. 1058-1066
    • Mardis, E.R.1    Ding, L.2    Dooling, D.J.3
  • 3
    • 84863393263 scopus 로고    scopus 로고
    • Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
    • Patel JP, Gönen M, Figueroa ME, et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366:1079-1089, 2012
    • (2012) N Engl J Med , vol.366 , pp. 1079-1089
    • Patel, J.P.1    Gönen, M.2    Figueroa, M.E.3
  • 4
    • 54849436885 scopus 로고    scopus 로고
    • Prognostic factors in elderly patients with AML and the implications for treatment
    • Erba HP: Prognostic factors in elderly patients with AML and the implications for treatment. Hematology Am Soc Hematol Educ Program 420-428, 2007
    • (2007) Hematology Am Soc Hematol Educ Program , pp. 420-428
    • Erba, H.P.1
  • 5
    • 34247525120 scopus 로고    scopus 로고
    • Advances in the management of AML in the elderly
    • Estey EH: Advances in the management of AML in the elderly. Clin Adv Hematol Oncol 5:185-187, 2007
    • (2007) Clin Adv Hematol Oncol , vol.5 , pp. 185-187
    • Estey, E.H.1
  • 6
    • 77950480200 scopus 로고    scopus 로고
    • Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
    • Walter RB, Kantarjian HM, Huang X, et al: Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 28:1766-1771, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 1766-1771
    • Walter, R.B.1    Kantarjian, H.M.2    Huang, X.3
  • 7
    • 70349451999 scopus 로고    scopus 로고
    • High-dose daunorubicin in older patients with acute myeloid leukemia
    • Löwenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235-1248, 2009
    • (2009) N Engl J Med , vol.361 , pp. 1235-1248
    • Löwenberg, B.1    Ossenkoppele, G.J.2    Van Putten, W.3
  • 8
    • 0037158110 scopus 로고    scopus 로고
    • The outcomes and costs of acute myeloid leukemia among the elderly
    • Menzin J, Lang K, Earle CC, et al: The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 162:1597-1603, 2002
    • (2002) Arch Intern Med , vol.162 , pp. 1597-1603
    • Menzin, J.1    Lang, K.2    Earle, C.C.3
  • 9
    • 33947205565 scopus 로고    scopus 로고
    • A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    • Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114-1124, 2007
    • (2007) Cancer , vol.109 , pp. 1114-1124
    • Burnett, A.K.1    Milligan, D.2    Prentice, A.G.3
  • 10
    • 77957732415 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin: Is there room for salvage?
    • Clarke WT, Marks PW: Gemtuzumab ozogamicin: Is there room for salvage? Blood 116:2618-2619, 2010
    • (2010) Blood , vol.116 , pp. 2618-2619
    • Clarke, W.T.1    Marks, P.W.2
  • 11
    • 77649194028 scopus 로고    scopus 로고
    • Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia
    • Schiller GJ, O'Brien SM, Pigneux A, et al: Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol 28:815-821, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 815-821
    • Schiller, G.J.1    O'Brien, S.M.2    Pigneux, A.3
  • 12
    • 77449159668 scopus 로고    scopus 로고
    • Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors
    • Kantarjian HM, Erba HP, Claxton D, et al: Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28:549-555, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 549-555
    • Kantarjian, H.M.1    Erba, H.P.2    Claxton, D.3
  • 13
    • 69849092737 scopus 로고    scopus 로고
    • A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
    • Harousseau JL, Martinelli G, Jedrzejczak WW, et al: A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 114:1166-1173, 2009
    • (2009) Blood , vol.114 , pp. 1166-1173
    • Harousseau, J.L.1    Martinelli, G.2    Jedrzejczak, W.W.3
  • 14
    • 80052592899 scopus 로고    scopus 로고
    • Phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance or presence of other comorbidities
    • abstr 604
    • Garcia-Manero G, Estey EH, Jabbour E, et al: Phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance or presence of other comorbidities. Blood 116, 2011 (abstr 604)
    • (2011) Blood , vol.116
    • Garcia-Manero, G.1    Estey, E.H.2    Jabbour, E.3
  • 15
    • 79959586108 scopus 로고    scopus 로고
    • Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: Results from an internet-based survey
    • Sekeres MA, Maciejewski JP, List AF, et al: Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: Results from an internet-based survey. Oncologist 16:904-911, 2011
    • (2011) Oncologist , vol.16 , pp. 904-911
    • Sekeres, M.A.1    Maciejewski, J.P.2    List, A.F.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.